Future studies would benefit from a longitudinal design with measurement of direct markers of cancer progression through imaging or laboratory assessment (eg, carcinoembryonic antigen [CEA], cancer antigen 125 [CA-125], alpha-fetoprotein [AFP], PSA, circulating transfer DNA). The gene discussed is MUC16; the disease is cancer.